Records Show Boehringer Ingelheim Corporation Did Not Disclose Pradaxa Analysis To FDA

Published: Feb 26, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Boehringer Ingelheim GmbH didn’t disclose a data analysis to U.S. regulators that indicated the blood-thinner Pradaxa may have caused more fatal bleeding after it was cleared for sale than the drug did in a study used to win approval, unsealed court filings show. Boehringer gave U.S. regulators one analysis of data gathered after the drug’s October 2010 approval that showed the number of people who died from bleeding was less than expected, according to internal documents made public in lawsuits over the product. The company didn’t share a second analysis showing a higher death rate, the documents show.

Help employers find you! Check out all the jobs and post your resume.

Back to news